Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27:5887–92.
PubMed
Article
Google Scholar
Malone KE, Begg CB, Haile RW, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010;28:2404–10.
PubMed
Article
CAS
Google Scholar
Metcalfe KA, Lynch HT, Ghadirian P, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005;96:222–6.
PubMed
Article
CAS
Google Scholar
Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999;8:855–61.
PubMed
CAS
Google Scholar
Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer. 2007;43:867–76.
PubMed
Article
CAS
Google Scholar
Daly M, Axilbund JE, Bryant E, et al. The NCCN genetic/familial high-risk assessment: breast and ovarian clinical practice guideline, version 1.2006. http://www.nccn.org/. Accessed 1 Oct 2006.
Boughey JC, Hoskin TL, Degnim AC, et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol. 2010;17:2702–9.
PubMed
Article
Google Scholar
Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. J Am Med Assoc. 2010;304:967–75.
Article
CAS
Google Scholar
Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. J Am Med Assoc. 2006;296:185–92.
Article
CAS
Google Scholar
Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2004;22:1055–62.
PubMed
Article
Google Scholar
Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91:1475–9.
PubMed
Article
CAS
Google Scholar
Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006;118:2281–4.
PubMed
Article
CAS
Google Scholar
King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention trial. J Am Med Assoc. 2001;286:2251–6.
PubMed
Article
CAS
Google Scholar
Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary breast cancer clinical study group. Lancet. 2000;356:1876–81.
PubMed
Article
CAS
Google Scholar
Daly M, Axilbund JE, Bryant E, et al. The NCCN genetic/familial high-risk assessment: breast and ovarian clinical practice guideline, version 1.2009. http://www.nccn.org/. Accessed 3 Dec 2009.
Earle CC. Failing to plan is planning to fail: improving the quality of care with survivorship care plans. J Clin Oncol. 2006;24:5112–6.
PubMed
Article
Google Scholar
Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor: lost in transition. Washington, DC: National Academies Press, 2005.
Google Scholar
American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397–406.
Google Scholar
Robson ME, Storm CD, Weitzel J, et al. American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010;28:893–901.
PubMed
Article
Google Scholar
Berliner JL, Fay AM. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the national society of genetic counselors. J Genet Couns. 2007;16:241–60.
PubMed
Article
Google Scholar
Fraser FC. Genetic counseling. Am J Hum Genet. 1974;26:636–61.
PubMed
CAS
Google Scholar
Bernhardt BA, Biesecker BB, Mastromarino CL. Goals, benefits, and outcomes of genetic counseling: client and genetic counselor assessment. Am J Med Genet. 2000;94:189–97.
PubMed
Article
CAS
Google Scholar
Shiloh S, Avdor O, Goodman RM. Satisfaction with genetic counseling: dimensions and measurement. Am J Med Genet. 1990;37:522–9.
PubMed
Article
CAS
Google Scholar
Pilnick A, Dingwall R. Research directions in genetic counselling: a review of the literature. Patient Educ Couns. 2001;44:95–105.
PubMed
Article
CAS
Google Scholar
Braithwaite D, Emery J, Walter F, et al. Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2004;96:122–33.
PubMed
Article
Google Scholar
Lerman C, Croyle RT, Tercyak KP, Hamann H. Genetic testing: psychological aspects and implications. J Consult Clin Psychol. 2002;70:784–97.
PubMed
Article
Google Scholar
Meiser B. Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psychooncology. 2005;14:1060–74.
PubMed
Article
Google Scholar
Hamann HA, Somers TJ, Smith AW, et al. Posttraumatic stress associated with cancer history and BRCA1/2 genetic testing. Psychosom Med. 2005;67:766–72.
PubMed
Article
Google Scholar
Vadaparampil ST, Miree CA, Wilson C, Jacobsen PB. Psychosocial and behavioral impact of genetic counseling and testing. Breast Dis. 2007;27:97–108.
Google Scholar
Schlich-Bakker KJ, Warlam-Rodenhuis CC, van Echtelt J, et al. Short term psychological distress in patients actively approached for genetic counselling after diagnosis of breast cancer. Eur J Cancer. 2006;42:2722–8.
PubMed
Article
Google Scholar
Vadaparampil ST, Quinn GP, Brzosowicz J, Miree CA. Experiences of genetic counseling for BRCA1/2 among recently diagnosed breast cancer patients: a qualitative inquiry. J Psychosoc Oncol. 2008;26:33–52.
PubMed
Article
Google Scholar
Geer KP, Ropka ME, Cohn WF, et al. Factors influencing patients’ decisions to decline cancer genetic counseling services. J Genet Couns. 2001;10:25–40.
PubMed
Article
CAS
Google Scholar
Nusbaum RH, Peshkin BN, DeMarco TA, Goodenberger M. BRCA
1/2 testing in patients with newly diagnosed breast cancer. Commun Oncol. 2009;6:367–71.
Article
Google Scholar
Lerman C, Schwartz MD, Lin TH, et al. The influence of psychological distress on use of genetic testing for cancer risk. J Consult Clin Psychol. 1997;65:414–20.
PubMed
Article
CAS
Google Scholar
Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast–ovarian cancer. A prospective study of patient decision making and outcomes. J Am Med Assoc. 1996;275:1885–92.
PubMed
Article
CAS
Google Scholar
Lerman C, Biesecker B, Benkendorf JL, et al. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. J Natl Cancer Inst. 1997;89:148–57.
PubMed
Article
CAS
Google Scholar
Hopwood P, Shenton A, Lalloo F, et al. Risk perception and cancer worry: an exploratory study of the impact of genetic risk counselling in women with a family history of breast cancer. J Med Genet. 2001;38:139.
PubMed
Article
CAS
Google Scholar
Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med. 1979;41:209–18.
PubMed
CAS
Google Scholar
Vadaparampil ST, Ropka ME, Stefanek ME. Measurement of psychological factors associated with genetic testing for hereditary breast, ovarian and colon cancers. Fam Cancer. 2005;4:195–206.
PubMed
Article
Google Scholar
Wevers MR, Ausems MG, Verhoef S, et al. Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial. BMC Cancer. 2011;11:6.
PubMed
Article
Google Scholar
Thewes B, Meiser B, Hickie IB. Psychometric properties of the Impact of Event Scale amongst women at increased risk for hereditary breast cancer. Psychooncology. 2001;10:459–68.
PubMed
Article
CAS
Google Scholar
Schwartz MD, Lerman C, Brogan B, et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol. 2004;22:1823–9.
PubMed
Article
Google Scholar
O’Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995;15:25–30.
PubMed
Article
Google Scholar
O’Connor AM. User manual—decisional conflict scale. Ottawa: Ottawa Hospital Research Institute, 1993, updated 2010.
Google Scholar
Cranney A, O’Connor AM, Jacobsen MJ, et al. Development and pilot testing of a decision aid for postmenopausal women with osteoporosis. Patient Educ Couns. 2002;47:245–55.
PubMed
Article
Google Scholar
Man-Son-Hing M, Laupacis A, O’Connor AM, et al. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. J Am Med Assoc. 1999;282:737–43.
PubMed
Article
CAS
Google Scholar
Stacey D, DeGrasse C, Johnston L. Addressing the support needs of women at high risk for breast cancer: evidence-based care by advanced practice nurses. Oncol Nurs Forum. 2002;29:E77–84.
PubMed
Article
Google Scholar
Sawka CA, Goel V, Mahut CA, et al. Development of a patient decision aid for choice of surgical treatment for breast cancer. Health Expect. 1998;1:23–36.
PubMed
Article
Google Scholar
O’Connor AM, Tugwell P, Wells GA, et al. A decision aid for women considering hormone therapy after menopause: decision support framework and evaluation. Patient Educ Couns. 1998;33:267–79.
PubMed
Article
Google Scholar
O’Connor AM, Tugwell P, Wells GA, et al. Randomized trial of a portable, self-administered decision aid for postmenopausal women considering long-term preventive hormone therapy. Med Decis Making. 1998;18:295–303.
PubMed
Article
Google Scholar
Trivers KF, Baldwin LM, Miller JW, et al. Reported referral for genetic counseling or BRCA
1/2 testing among United States physicians: a vignette-based study. Cancer. 2011;117:5334–43.
PubMed
Article
Google Scholar
Meyer LA, Anderson ME, Lacour RA, et al. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol. 2010;115:945–52.
PubMed
Article
Google Scholar
Vadaparampil ST, Quinn GP, Miree CA, et al. Recall of and reactions to a surgeon referral letter for BRCA genetic counseling among high-risk breast cancer patients. Ann Surg Oncol. 2009;16:1973–81.
PubMed
Article
Google Scholar
O’Neill SM, Peters JA, Vogel VG, et al. Referral to cancer genetic counseling: are there stages of readiness? Am J Med Genet C Semin Med Genet. 2006;142C:221–31.
PubMed
Article
Google Scholar
Levy DE, Byfield SD, Comstock CB, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med. 2011;13:349–55.
PubMed
Article
Google Scholar
Clarke A, Parsons E, Williams A. Outcomes and process in genetic counselling. Clin Genet. 1996;50:462–9.
PubMed
Article
CAS
Google Scholar
Bowen DJ, Burke W, McTiernan A, et al. Breast cancer risk counseling improves women’s functioning. Patient Educ Couns. 2004;53:79–86.
PubMed
Article
Google Scholar
Meiser B, Halliday JL. What is the impact of genetic counselling in women at increased risk of developing hereditary breast cancer? A meta-analytic review. Soc Sci Med. 2002;54:1463–70.
Google Scholar
Bellcross CA, Kolor K, Goddard KA, et al. Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians. Am J Prev Med. 2011;40:61–6.
PubMed
Article
Google Scholar